Format

Send to

Choose Destination
Plant Biotechnol J. 2015 Oct;13(8):1199-208. doi: 10.1111/pbi.12428. Epub 2015 Jun 23.

Large-scale production of pharmaceutical proteins in plant cell culture-the Protalix experience.

Author information

1
Protalix Biotherapeutics, Carmiel, Israel.

Abstract

Protalix Biotherapeutics develops recombinant human proteins and produces them in plant cell culture. Taliglucerase alfa has been the first biotherapeutic expressed in plant cells to be approved by regulatory authorities around the world. Other therapeutic proteins are being developed and are currently at various stages of the pipeline. This review summarizes the major milestones reached by Protalix Biotherapeutics to enable the development of these biotherapeutics, including platform establishment, cell line selection, manufacturing process and good manufacturing practice principles to consider for the process. Examples of the various products currently being developed are also presented.

KEYWORDS:

Protalix Biotherapeutics; enzyme replacement therapy; molecular farming; oral delivery; plant cell culture; β-glucocerebrosidase

PMID:
26102075
DOI:
10.1111/pbi.12428
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center